Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Inclusion Criteria: * De novo and primary Ph/BCR-ABL1 negative acute lymphoblastic leukemia diagnosed by the bone marrow cytomorphology, immunophenotyping, cytogenetics and molecular biology according to WHO classification * Age: 14 -60 years * Male or female * ECOG Performance Status 0-2 * Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of normal（ULN）; serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liver is present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasound ejection fraction ≥ 45%; * Subject has provided written informed consent prior to any screening procedure Exclusion Criteria: * Burkitt lymphoma/leukemia * Acute Leukemia of Ambiguous Lineage * Female patients who are pregnant or breast feeding * Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment * History of pancreatitis * Poorly controlled diabetes, defined as glycosylated hemoglobin (HbA1c) values of \>7.5%. Patients with preexisting, well-controlled diabetes are not excluded * History of active gastrointestinal bleeding within the last 6 months * History of arterial/venous thrombosis within the last 6 months * Known HIV seropositivity * Any serious psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment